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Purpose: The purpose of the study is to assess the validity of codes or algorithms
used to identify dementia in UK electronic health record (EHR) primary care and
hospitalisation databases.
Methods: Relevant studies were identified by searching the MEDLINE/EMBASE
databases from inception to June 2018, hand‐searching reference lists, and consulting
experts. The search strategy included synonyms for “Dementia”, “Europe”, and “EHR”.
Studies were included if they validated dementia diagnoses in UK primary care or
hospitalisation databases, irrespective of validation method used. The Quality Assess-
ment for Diagnostic Accuracy Studies‐2 (QUADAS‐2) toolwas used to assess risk of bias.
Results: From 1469 unique records, 14 relevant studies were included. Thirteen
validated individual diagnoses against a reference standard, reporting high estimates
of validity. Most reported only the positive predictive value (PPV), with estimates
ranging between 0.09 and 1.0 and 0.62 and 0.85 in primary care and hospitalisation
databases, respectively. One study performed a rate comparison, indicating good
generalisability of dementia diagnoses in The Health Improvement Network (THIN)
database to the UK population. Studies were of low methodological quality. As
studies were not comparable, no summary validity estimates were produced.
Conclusion: While heterogenous across studies, reported validity estimates were
generally high. However, the credibility of these estimates is limited by the methodo-
logical quality of studies, primarily resulting from insufficient blinding of researchers
interpreting the reference test. Inadequate reporting, particularly of the specific codes
validated, hindered comparison of estimates across studies. Future validation studies
should make use of more robust reference tests, follow established reporting
guidelines, and calculate all measures of validity.
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• No prior review has systematically identified and
appraised studies validating diagnostic codes/
algorithms for dementia in UK electronic health records.
• Among the 14 included studies, the PPV of codes used
to identify dementia ranged from 0.09 to 1.0 and 0.62
to 0.85 in primary and secondary care databases,
respectively.
• Although reported estimates of validity were relatively
high, all studies were at significant risk of bias.
• Few studies reported NPV, sensitivity, or specificity.
Reporting PPV alone limits the generalisability of
results to study periods with a different dementia
prevalence.
• Future research is needed to develop and validate “best‐
practice” dementia codes/algorithms for use in distinct
EHR databases.1 | INTRODUCTION
The burden of dementia and its associated health and societal costs
are projected to have major global impact as populations continue to
age over the next few decades, despite the recent decline in age‐
specific dementia incidence.1 With only one‐third of cases being
due to potentially modifiable risk factors and in the absence of
effective treatments,2 there is an urgent need for adequately
powered studies seeking to identify dementia determinants. The
recent widespread adoption of routine electronic health records
(EHR) offers an opportunity to conduct powerful, efficient popula-
tion‐based studies into dementia causes and outcomes. However,
the advantages associated with the use of EHR data rely on the
codes/algorithms used to identify dementia cases in these databases
being valid.
Several large UK‐based EHR databases exist and are regularly
used for research purposes, including the Clinical Practice Research
Datalink (CPRD, formerly known as the GPRD), which as of 2013 cov-
ered ~7% of the UK population,3 and the Hospital Episode Statistics
Admitted Patient Care (HES‐APC) database, which contains details
on admissions to all National Health Service Trusts in England.4 Previ-
ous reviews have established the generally high validity of codes and
algorithms for multiple conditions in a single database, such as the
CPRD.5 However, no published systematic review has specifically
examined the validity of codes/algorithms used to identify dementia
cases across all UK EHR databases.
The objectives of this review were to systematically identify and
appraise studies validating diagnostic codes/algorithms for dementia
in UK primary care and hospitalisation electronic health records, sum-
marise their results to identify best‐practice codes/algorithms for
dementia in each distinct database, and to highlight gaps in the litera-
ture to inform future research.2 | METHODS
We performed a systematic review of studies validating dementia
diagnoses in UK primary or secondary care electronic health records.
This review was conducted in accordance with the guidelines of the
Cochrane Collaboration Diagnostic Test Accuracy handbook6 and the
PRISMA statement.72.1 | Eligibility criteria
We sought to include primary studies that validated a code or algo-
rithm used to identify dementia cases in a UK population‐based
primary care or hospitalisation EHR database. Acceptable methods
of validation included comparison against a reference standard
(for example, GP questionnaire, case note review, external database,
or disease‐specific registry) or a comparison of rates with external
population‐based data. Case note review in this context refers to a
thorough review of the entire patient record, including the free text
fields of the EHR database and copies of hospital letters, when avail-
able. To be included, a study validating individual diagnoses against a
reference standard must have reported at least one measure ofvalidity, namely the positive predictive value (PPV), negative predictive
value (NPV), sensitivity, or specificity, or the raw data to allow for its
calculation. No restrictions were made relating to the UK database
examined, the language or date of publication, or the number of vali-
dations performed. Conference abstracts were included, if eligible,
provided the relevant details could be obtained from the authors.
We did not include validations of dementia diagnoses in death
certificates or disease‐specific registries, as these were considered
beyond the scope of this review. Studies validating only the date of
diagnosis were excluded.2.2 | Search strategy
We searched MEDLINE and EMBASE from inception to 25 June
2018. Searches used a combination of free text and controlled vocab-
ulary terms to identify studies conducted in UK EHR databases in
which a diagnostic validation of dementia was reported. The search
strategy included synonyms for “Dementia” AND “Europe” AND
“EHR” (Appendix 1). We did not include synonyms for “Validity” as it
had previously been shown that terms relating to the validation of
diagnoses are often not mentioned in the searchable terms of a refer-
ence (the title, abstract, and controlled vocabulary), particularly when
validation represented only a small aspect of a larger study.5,8 We
used synonyms for Europe in place of terms for the UK, as we had
identified some records examining multiple European EHR sources
that contained information relevant to UK databases, but were not
captured by a search incorporating only UK terms. We also searched
for synonyms of “Dementia” AND UK‐specific databases such as
the CPRD.
Bibliographies of the CPRD,9 the Boston Collaborative Drug
Surveillance Programme,10 and The Health Improvement Network
(THIN)11 were hand‐searched to identify additional relevant articles.
246 MCGUINNESS ET AL.The bibliographies of systematic reviews of the validity of multiple
diagnoses contained within UK EHR databases, identified both
through consultation with subject matter experts and through the
search strategy, were screened for potentially relevant articles.
Finally, the reference lists of included studies were screened, while
the articles that had cited included studies were examined using
Google Scholar.2.3 | Study selection
The titles and abstracts of retrieved references were screened to iden-
tify studies that possibly examined UK EHR data. Only when it was
clear that a study did not use EHR data (for example, the abstract
listed the specific European countries/databases examined) was a
reference excluded. The full texts of all remaining studies were then
assessed for inclusion in the review. Eligibility assessment was per-
formed by one reviewer (L.A.M.), with a second reviewer (L.R.M.)
independently assessing a random sample of 30% of references at
each stage to verify the screening process.2.4 | Data extraction
Data extraction was performed by one reviewer (L.A.M.) using a
standardised data abstraction form and was reexamined by a second
reviewer (L.R.M.) to ensure accuracy. When the relevant details were
not adequately reported in the study's publication, the primary author
was contacted. We extracted data on the study authors, date of pub-
lication, setting, study period, database, diagnostic codes (OXMIS,
Read, International Classification of Diseases) used to define demen-
tia, characteristics of the study population, validation method used,
number and proportion of identified dementia cases that were
validated and measures of validity reported (PPV, NPV, sensitivity,
specificity), or the raw data to allow their calculation.2.5 | Quality assessment
The studies included in this review most closely resemble diagnostic
accuracy studies. Based on this, we used the Quality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS‐2) tool,12 tailored to our
review question, to assess the risk of bias and applicability of included
studies which validated a dementia diagnosis using a reference
standard. QUADAS‐2 consists of four domains (study design and
patient selection, index test, reference standard, flow and timing), with
each being assessed in terms of risk of bias and the first three in terms
of applicability concerns. In the context of this review, the phrase
“index test” refers to the codes/algorithms which were tested for
their ability to accurately define a dementia diagnosis. Each study
was initially assessed by one reviewer (L.A.M.), and the risk of bias
judgements made was reevaluated by a second researcher (L.R.M.).
Disagreements were resolved by discussion with a senior member of
the review team (S.L.T.).2.6 | Analysis
For each included study which validated individual diagnoses against a
reference standard, the PPV, NPV, sensitivity, and specificity of thecode/algorithm examined were calculated when necessary from the
raw data, along with 95% confidence intervals.13,14 Stata Statistical
Software Package version 14.0 (StataCorp LP, College Station, TX,
USA) was used to present coupled forest plots of the PPV/NPV
and sensitivity/specificity,15 stratified by setting (primary care vs
hospitalisation), EHR database, and dementia type. Studies validating
<10 dementia cases were excluded from the plots.
Due to a lack of comparable studies following stratification,
summary estimates of validity could not be produced, and a formal
assessment of heterogeneity and publication bias could not be per-
formed. As an exploratory analysis, the heterogeneity between the
PPV estimates within strata was examined using a χ2 test.133 | RESULTS
3.1 | Literature search
We identified 2055 records through the database search and bibli-
ography screening (Figure 1). Following deduplication, the titles and
abstracts of 1469 unique records were screened for inclusion in
the review, of which 975 were determined not to be primary valida-
tion studies of a UK database. Fourteen of the 494 remaining stud-
ies were included after full‐text screening. Reasons for exclusion at
this stage included lack of a dementia diagnoses validation
(n = 476), duplicate reporting of a previous published validation
(n = 3), and a conference abstract for which no further information
could be obtained (n = 1).3.2 | Characteristics of included studies
Fourteen references met the inclusion criteria (Table 1),16-29 of which
13 used reference standards to validate individual diagnoses of
dementia within an EHR database. Half of the included studies had
validation of diagnoses as the primary aim of the study (n = 7). Seven
studies were UK‐wide, four examined Scottish EHR databases, and
three examined an English database. Ten studies examined primary
care databases, with the CPRD being the most commonly validated
(n = 6), while four examined hospitalisation data. Half (n = 7) of the
included studies specified the exact codes/algorithms that they sought
to validate (Table 2).3.3 | Validity of dementia diagnosis
The 13 studies which used a reference standard reported 55 individual
validity estimates (Table 3). Five studies only validated patients with a
positive index test, reporting PPV as the sole validity measure. Three
studies reported more than one PPV within the same paper, with
two separate algorithms being compared against the same reference
standard in the first,18 the same code/algorithm being compared
against two separate reference standards in the second,27 and three
separate algorithms being compared against two distinct reference
standards in the third.16
The estimates for each measure of validity, along with their 95%
confidence intervals, are summarised in Figures 2 and 3. The PPV esti-
mates reported varied between 0.09 and 1.0 in primary care databases
FIGURE 1 PRISMA flow chart
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(Whitelaw et al17) was included inTable 1 but excluded from the forest
plots due to both data scarcity (only three validations performed) and
suboptimal reporting making it difficult to determine how the primary
analysis was conducted.
One study conducted a rate comparison to validate a dementia
code/algorithm, using the same set of codes to calculate the crude
prevalence rates from both the THIN database and national Quality
and Outcomes Framework (QOF) data for 2006 to 2007. While not
directly providing validity measures, the estimated prevalence in the
THIN database was slightly higher but comparable to that of the
QOF data (0.47% ± 0.03% vs 0.42%, respectively).243.4 | Risk of bias assessment
In Figure 4, we present the summary of our risk of bias assessment of
included studies using the QUADAS‐2 tool. In general, studies had low
internal validity, with all having a high risk of bias in at least one
domain. For the study design and patient selection domain, the
method used to select the subset of cases for validation was often
not clearly stated. Application of the index test was at low risk of bias
for almost all studies. Conversely, most studies were at high risk of
bias related to application of the reference test, as few studies suffi-
ciently blinded researchers to the results of the index test when
interpreting the reference test (Appendix 2).
Assessment of the flow and timing domain of the QUADAS‐2 tool
proved particularly challenging, as for most studies, the time between
application of the reference and index tests was not clearly stated,
allowing for potential delayed verification bias.
All studies had low concerns regarding their applicability to the
review question. This was expected due to the necessarily broad
review question.3.5 | Heterogeneity
There was evidence for heterogeneity between the PPV estimates for
Alzheimer's (n = 7; χ2 test for homogeneity of proportions = 1400;
P < 0.001) and dementia (n = 4; χ2 test = 3100; P < 0.001) in the
CPRD, dementia in HES (n = 3; χ2 test = 9.44; P = 0.009), and demen-
tia in SMR (n = 2; χ2 test = 15.64; P < 0.001). No evidence for hetero-
geneity was observed between PPV estimates for dementia in HES (χ2
test = 0.032, P = 0.857).4 | DISCUSSION
4.1 | Summary
The studies identified in this review included a range of settings, EHR
databases, and dementia subtypes and validated varying codes/algo-
rithms used to identify dementia. Validity estimates were generally
high, though were heterogeneous across studies. Generally, poor
reporting made it difficult to interpret and compare estimates of valid-
ity across studies, particularly as not all studies reported the specific
code/algorithm validated.4.2 | Validity estimates
Several included studies which compared individual diagnoses to a ref-
erence standard reported solely the PPV of the code/algorithm they
examined, a similar finding to previous reviews of EHR validation stud-
ies.5 PPV estimates were generally high, although they varied substan-
tially between studies, ranging from 0.09 to 1.0 in primary care data
and 0.62 to 0.85 in hospitalisation data. While the PPV is a useful
measure, it is dependent on the prevalence of the dementia in the
population at the time of study, and so its generalisability to different
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TABLE 2 Summary of diagnoses validated in the seven studies which reported the specific codes validated
Study
Coding
System
Diagnosis
Validated
Specific Codes/Algorithms Representing
the Diagnosis Notes
Walker, 2018 READ Probable AD Any of: Eu00.00, Eu00000, Eu00011,
Eu00012, Eu00013, Eu00100, Eu00111,
Eu00112, Eu00113, Eu00200, Eu00z00,
Eu00z11, F110.00, F110000, F110100,
Fyu3000
Patients may also have codes on the
“possible AD” list and codes representing
a prescription for a drug used exclusively
in the treatment of dementia, detailed in
BNF section 4.11, excluding idebenone.
Possible AD Any of: E00..00, E00..11, E00..12, E000.00,
E001.00, E001000, E001100, E001200,
E001300, E001z00, E002.00, E002000,
E002100, E002z00, E003.00, E00z.00,
Eu02z11, Eu02z12, Eu02z14, Eu02z15,
Eu02z16, Eu05700, F11z.11
Patients may also have codes on the
“possible AD” list and codes representing
a prescription for a drug used exclusively
in the treatment of dementia, detailed in
BNF section 4.11, excluding idebenone.
Non‐AD And
mixed
dementia
Any of: Eu02z13, Eu02z00, Eu02.00,
Eu02y00, 6AB..00, E041.00, 9hD1.00,
9hD0.00, E00y.00, F112.00, 8BPa.00,
E02y100, Eu01111, Eu02000, Eu02100,
Eu02200, Eu02300, Eu02400, Eu02500,
Eu04100, F111.00, F116.00, F11x200,
E004.00, E004.11, E004000, E004100,
E004200, E004300, E004z00, Eu01.00,
Eu01.11, Eu01000, Eu01100, Eu01200,
Eu01300, Eu01y00, Eu01z00 or any code
representing a prescription for a drug used
exclusively in the treatment of dementia,
detailed in BNF section 4.11, excluding
Idebenone
Patients may also have codes on the
“probable AD” and “possible AD” lists, but
due to the presence of a non‐AD specific
code, they do not meet the criteria for
these classifications.
Heath, 2015 READ Dementia Any of: 66 h, 6AB.., E00.., E000., E001.,
E0010, E0011, E0012, E0013, E001z,
E002., E0020, E0021, E002z, E003., E004.,
E0040, E0041, E0042, E0043, E004z,
E00y., E00z., E041., Eu00., Eu000, Eu001,
Eu002, Eu00z, Eu01., Eu010, Eu011,
Eu012, Eu013, Eu01y, Eu01z, Eu02.,
Eu020, Eu021, Eu022, Eu023, Eu024,
Eu025, Eu02y, Eu02z, F110., F1100,
F1101, F111., F112., F116., Fyu30(in
addition to codes representing a
prescription for a drug used exclusively in
the treatment of dementia, detailed in BNF
section 4.11)
Blak, 2011 READ Dementia Any of: E11.%, F212., F21Z, F371a
Sommerland, 2018 ICD‐10 Dementia Any of: F00x‐F03x, G30x, G31.0, G31.8
Brown, 2016 ICD‐10 Dementia Any of: E512, F00, F01, F02, F03, F10.6,
F10.7, G30, or G31.0.
Soo, 2014 ICD‐10 Dementia Any of: F01, F00, F03, F02, F05.1, G30,
G31.1
Ryan, 1994 ICD‐9b Dementia 290
Abbreviations: AD, Alzheimer's disease; ICD‐9, International Classification of Disease (9th Edition); ICD‐10, International Classification of Disease (10th
Edition).
aThe “%” symbol represents a wildcard for READ codes (ie, a search using E11.% would identify E11 and all codes nested under it).
bHarmonisation between ICD‐8 and ICD‐9 occurred for the period 1968 to 1979.
250 MCGUINNESS ET AL.study periods is limited. This limitation is particularly important in the
absence of the other measures of validity.
There is no universal threshold above which a PPV estimate is
deemed acceptable because the relative importance of a test's validity
is related to the specific consequences of misclassification. While gen-
erally high, some of the reported PPVs are likely suboptimal for the
accurate classification of a patient's dementia status in future
research, potentially introducing strong bias into a study performed
using the corresponding code/algorithm.
Eight studies reported additional measures of validity. Like the
PPV, estimates varied over a wide range of values but were generallyhigh. An important exception is the low sensitivity (0.3, 95% CI: 0.24‐
0.37) of an algorithm to identify dementia in the Scottish Mortality
Records (SMR) database. One possible explanation for this is the
restricted population (patients identified as having moderate/severe
chronic kidney disease during study period).
The within‐strata heterogeneity of PPV estimates may primarily
be explained by the differing time periods examined by individual
studies. However, the contrast between the PPV estimates reported
in two studies by Dunn et al merits further discussion. Although these
studies were performed by the same author and are identical in terms
of reported study characteristics, both were included in this review
TABLE 3 Summary of results of studies included in the review (stratified by setting, database, and dementia type)
Study
Diagnosis
Validated
Validation
Method
Index Dementia Positive Index Dementia Negative
Number
Identified in
Database
Number
Chosen for
Validation
Number with
Available
Data (%)
Number
Identified in
Database
Number
Chosen for
Validation
Number
with Available
Data (%)
Walker, 201816 Probable AD Comparison against HES 8069 8069 8069 (100%) 21 293 21 293 21293 (100%)
Comparison against ONS 8069 8069 8069 (100%) 21 293 21 293 21293 (100%)
Possible AD Comparison against HES 8259 8259 8259 (100%) 21 103 21 103 21103 (100%)
Comparison against ONS 8259 8259 8259 (100%) 21 103 21 103 21103 (100%)
Non‐AD and
mixed
dementia
Comparison against HES 13 034 13 034 13 034 (100%) 16 328 16 328 16328 (100%)
Comparison against ONS 13 034 13 034 13034 (100%) 16 328 16 328 16328 (100%)
Whitelaw, 199617a Dementia Case note review ? ? ? ? ? ?
Seshadri, 200118 AD Case note review 128 128 128 (100%) ‐ ‐ ‐
AD Case note review 51 51 51 (100%) ‐ ‐ ‐
Imfeld, 201219 AD GP confirmation 7086 60 60 (100%) ‐ ‐ ‐
Dunn, 2005 20 (a)b Dementia GP confirmation 9954 150 150 (100%) 9347 50 50 (100%)
Dunn, 200521 (b)b Dementia GP confirmation 9954 100 95 (95%) 9374 50 55 (110%)c
Imfeld, 201322 VaD GP confirmation 4438 60 60 (100%) ‐ ‐ ‐
Heath, 201523 Dementia Case note review 15 15 15 ‐ ‐ ‐
Van Staa, 199425 Dementia GP confirmation NS NS 12 (−%) ‐ ‐ ‐
Dementia GP confirmation NS NS 9 (−%) ‐ ‐ ‐
Sommerland,
201826
Dementia Comparison against CRIS 8069 8069 8069 13 318 13 318 13318
Brown, 201627 Dementia Comparison against CPRD 340 340 340 (100%) ‐ ‐ ‐
Dementia GP confirmation NS 333 244 (73%) NS 1004 866 (86%)
Ryan, 199429 Dementia Case note review 1988 200 146 (73%) ‐ ‐ ‐
Soo, 201428d Dementia Case note review 91 91 91 (100%) 3128 3128 3128 (100%)
Abbreviations: AD, Alzheimer's disease; CRIS, Clinical Record Interactive Search at South London and Maudsley; FN, false negative; FP, false positive; HES,
Hospital Episode Statistics; ONS, Office for National Statistics; NS, not stated; TN, true negative; TP, true positive; VaD, vascular dementia.
aPrimary analysis unclear, reported validity estimates displayed for reference.
bSeparate studies performed by same author in same year.
cMore cases were validated than were specified in the study's methods.
d95% CI was only reported by this study. For the remainder, the CIs were calculated using the Wilson method.
MCGUINNESS ET AL. 251as the very different PPVs (0.83 vs 1) suggest that a different algo-
rithm was used in each.20,21 However, the specific codes validated
were not reported so it remains possible that these studies had over-
lapping validation cohorts. Further, it is important to note that this
heterogeneity assessment was exploratory and susceptible to bias as
the χ2 test does not account for the paired nature of validity measures.4.3 | Methodological quality
Overall, the methodological quality of studies was suboptimal, with all
studies having at least one high/unclear risk of bias domain. This related
particularly to the reference standard used, primarily due to insufficient
blinding of researchers. Blinding in EHR validation studies is seldom
considered, and in the common scenario when only the PPV is being
assessed, blinding those interpreting the reference test is not possible
(because all included patients will have been diagnosed with dementia
by the index test). Nevertheless, the extent to which researchers might
be influenced by knowledge of the index test result is an interesting
issue and merits further discussion. The scope for misclassification of
dementia status by the reference standard also led to a high risk of bias
judgement in several studies, for example, by estimating the PPV of
HES using the CPRD as reference standard.27 Furthermore, thedefinition of GP confirmation may differ between studies, with the
potential to bias the estimates of validity reported; a reference standard
that solely asks a GP whether a given patient has dementia is likely to
have more misclassification than one which asks for copies of relevant
tests/prescriptions to support the diagnosis.
A further two methodological limitations were not assessed by
QUADAS‐2 but impacted the strength and generalisability of evidence
produced by included studies. Firstly, the proportion of identified
cases validated was often small, reducing the precision of the esti-
mates of validity reported. Secondly, as identified previously,5 the
validity estimates reported may not be generalisable to the entire
database. This issue is particularly relevant to primary care databases,
as not all practices take part in validation studies and data are often
not available for patients who have died or have left the practice.4.4 | Strengths and limitations
To the best of our knowledge, this is the first review to focus specifi-
cally on the validity of dementia diagnoses in UK EHR primary care
and hospitalisation databases. The comprehensiveness of the search
strategy, achieved by not restricting to studies that mentioned or
indexed validation terms and by an extensive bibliography and refer-
ence list search, is a major strength of this review.
TABLE 3 (Continued)
Study TP FP TN FN PPV NPV Sensitivity Specificity
Walker, 201816 2974 5095 19260 2033 0.37 (0.36‐0.38) 0.90 (0.90‐0.91) 0.59 (0.58‐0.61) 0.79 (0.79‐0.80)
1220 6849 20650 643 0.15 (0.14‐0.16) 0.97 (0.97‐0.97) 0.65 (0.63‐0.68) 0.75 (0.75‐0.76)
2410 5849 17052 4051 0.29 (0.28‐0.30) 0.81 (0.80‐0.81) 0.37 (0.36‐0.38) 0.74 (0.740.75)
1711 6548 18062 3041 0.21 (0.200.22) 0.86 (0.850.86) 0.36 (0.35‐0.37) 0.73 (0.730.74)
4444 8590 14566 1762 0.34 (0.33‐0.35) 0.89 (0.89‐0.90) 0.72 (0.70‐0.73) 0.63 (0.62‐0.64)
1171 11863 16043 285 0.09 (0.09‐0.09) 0.98 (0.98‐0.98) 0.80 (0.78‐0.82) 0.58 (0.57‐0.58)
Whitelaw, 199617a ‐ ‐ ‐ ‐ 1 ‐ 0 ‐
Seshadri, 200118 62 66 ‐ ‐ 0.48 (0.4‐0.57) ‐ ‐ ‐
43 8 ‐ ‐ 0.84 (0.72‐0.92) ‐ ‐ ‐
Imfeld, 201219 47 13 ‐ ‐ 0.79 (0.66‐0.87) ‐ ‐ ‐
Dunn, 2005 20 (a)b 150 0 50 0 1 (0.98‐1) 1 (0.93‐1) 1 (0.98‐1) 1 (0.93‐1)
Dunn, 200521 (b)b 79 16 55 0 0.83 (0.74‐0.89) 1 (0.93‐1) 1 (0.95‐1) 0.78 (0.66‐0.86)
Imfeld, 201322 44 16 ‐ ‐ 0.73 (0.61‐0.83) ‐ ‐ ‐
Heath, 201523 15 0 ‐ ‐ 1 (0.80‐1) ‐ ‐ ‐
Van Staa, 199425 12 0 ‐ 1 (0.76‐1) ‐ ‐ ‐
7 ‐ ‐ 2 ‐ ‐ 0.78 (0.45‐0.94) ‐
Sommerland, 201826 6429 1640 12 094 1817 0.80 (0.79‐0.81) 0.87 (0.86‐0.88) 0.78 (0.77‐0.79) 0.88 (0.88‐0.89)
Brown, 201627 288 52 ‐ ‐ 0.85 (0.80‐0.88) ‐ ‐ ‐
208 36 865 1 0.85 (0.80‐0.89) 1 (0.99‐1) 1 (0.97‐1) 0.965‐0.97)
Ryan, 199429 123 23 ‐ ‐ 0.84 (0.77‐0.89) ‐ ‐ ‐
Soo, 201428d 56 35 2997 131 0.62 (0.51‐0.71) 0.96 (0.95‐0.96) 0.3 (0.24‐0.37) 0.99 (0.98‐0.99)
FIGURE 2 Coupled forest plot of PPV/NPV estimates (stratified by setting, database, and dementia subtype)
252 MCGUINNESS ET AL.A key limitation of this review is that many of the included studies
did not use robust external reference diagnoses as a comparison to
the codes in the EHR databases. In diagnostic test accuracy studies,
it is assumed that the specificity and sensitivity of the reference test
is 1, and that any misclassification is introduced by the index test
alone. Clearly, this is not the case in the studies included in this review,
particularly when the reference test used is another EHR database,
and this fact may introduce bias into the estimates of validity reported.The QUADAS‐2 tool used in this study is not specifically designed
for the assessment of EHR validation studies. Thus, the potential for
misclassifying the internal validity of a study introduced by this mis-
match between study design and the risk of bias assessment tool is a lim-
itation specific to this review. This difficulty in accurately assessing risk
of bias was compounded by generally poor reporting of included studies.
An inability to assess whether publication bias is present, due to
an absence of available data, is a further weakness of this review.
FIGURE 3 Coupled forest plot of sensitivity/specificity estimates (stratified by setting, database, and dementia subtype)
FIGURE 4 Risk of bias in each included
study across the four QUADAS‐2 domains
(study design and patient selection, index test,
reference standard, and flow and timing)
[Colour figure can be viewed at
wileyonlinelibrary.com]
MCGUINNESS ET AL. 253Unlike randomised controlled trials, validation studies are often not
registered. This, combined with the fact that validation often forms a
small element of a larger study, may mean that researchers choose
simply not to report the results of the validation exercise. Ashigher estimates of validity are more likely to be included in a
publication, this may bias the results of this review towards
overstating the validity of the codes/algorithms used to identify
dementia.
254 MCGUINNESS ET AL.5 | CONCLUSIONS AND
RECOMMENDATIONS
Through this review, we found an absence of high‐quality published
literature examining the validity of different codes/algorithms for each
dementia type in UK primary care and hospitalisation EHR databases.
Several identified studies reported only the PPV, and a wide range of
values for this measure were reported. There is therefore a need to
develop, validate, and disseminate best practice codes/algorithms for
identifying dementia using routine electronic health data. In addition
to the PPV, future primary validation studies should calculate other
measures of validity, such as sensitivity and specificity, which are more
versatile and allow the code/algorithm to be used in a different study
period. Similarly, future studies should aim to validate a larger number
of cases to increase confidence in the estimates produced, and should
make use of robust reference tests, such as an independent clinical
examination based on established criteria, to reduce the potential for
bias introduced by weak gold standard tests. In line with standardised
reporting criteria, the codes/algorithms validated, in addition to a com-
prehensive description of the methods used, should be reported in the
study itself or in accompanying supplementary documents if space is
limited.8 Finally, a registry of ongoing and completed validation studies
conducted in UK EHR databases would help to avoid the duplication
of future work, provide a platform for the listing of “best‐practice”
algorithms, and reduce the potential for publication bias.
With regards to future systematic reviews of this topic, the devel-
opment and piloting of risk of bias tools specific to the validation
studies of EHR diagnoses is a priority, evidenced by the limited appli-
cability of QUADAS‐2 tool to included studies. More generally, future
reviews of EHR validation studies should ensure that terms for valida-
tion are omitted from their search strategies, a recommendation
consistent with previous reviews of this topic.5ETHICS STATEMENT
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